Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (RMPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). Conference

Omuro, Antonio Marcilio Padula, DeAngelis, Lisa Marie, Karrison, Theodore et al. (2020). Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (RMPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). . Journal of Clinical Oncology, 38(15),

International Collaboration

cited authors

  • Omuro, Antonio Marcilio Padula; DeAngelis, Lisa Marie; Karrison, Theodore; Bovi, Joe A; Rosenblum, Marc; Corn, Benjamin W; Correa, Denise; Wefel, Jeffrey Scott; Aneja, Sanjay; Grommes, Christian; Schaff, Lauren; Waggoner, Steven E; Lallana, Enrico C; Werner-Wasik, Maria; Iwamoto, Fabio; Robinson, Timothy J; Donnelly, Eric; Struve, Timothy; Won, Minhee; Mehta, Minesh P

sustainable development goals

authors

date/time interval

  • May 29, 2020 -

publication date

  • May 20, 2020

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

volume

  • 38

issue

  • 15